Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
Delayed Quote. Delayed Nasdaq - 03/30 04:00:00 pm
72.17 USD   +4.65%
03/26INCYTE CORP : Change in Directors or Principal Officers (form 8-K)
AQ
03/26INCYTE : Names New Member to Its Board of Directors
BU
03/26INCYTE CORPORATION : Nomination
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Novartis, Incyte : Capmatinib Gets FDA Priority Review

share with twitter share with LinkedIn share with facebook
share via e-mail
02/11/2020 | 06:29am EDT

By Colin Kellaher

 

Novartis AG (NOVN.EB, NVS) and Incyte Corp. (INCY) Tuesday said the U.S. Food and Drug Administration accepted and granted priority review to a new drug application for capmatinib in a form of non-small cell lung cancer.

The companies said the filing covers capmatinib as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping mutated non-small cell lung cancer.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months.

Novartis and Incyte said capmatinib, if approved, would be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis.

Incyte, a Wilmington, Del., biopharmaceutical company, discovered capmatinib and in 2009 granted Swiss drug maker Novartis exclusive worldwide development and commercialization rights to the compound in all indications.

Incyte said it could be eligible for more than $500 million in milestone payments, along with royalties on global sales, if Novartis successfully develops capmatinib.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
INCYTE CORPORATION 4.65% 72.17 Delayed Quote.-21.03%
NOVARTIS 1.53% 79.17 Delayed Quote.-15.34%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on INCYTE CORPORATION
03/26INCYTE CORP : Change in Directors or Principal Officers (form 8-K)
AQ
03/26INCYTE : Names New Member to Its Board of Directors
BU
03/26INCYTE CORPORATION : Nomination
CO
03/24INCYTE : Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermati..
BU
03/16ELI LILLY, INCYTE : Baricitinib Gets FDA Breakthrough Designation in Alopecia Ar..
DJ
03/11INCYTE CORPORATION : Report
CO
03/05INCYTE : MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,62..
AQ
03/04INCYTE : MorphoSys and Incyte Announce Antitrust Clearance of Global Collaborati..
AQ
03/03FDA Accepts MorphoSys Biologics License Application and Grants Priority Revie..
AQ
02/27INCYTE : Partners with Artist and Patient J.G. Jones to Raise Awareness for Myel..
BU
More news
Financials (USD)
Sales 2020 2 419 M
EBIT 2020 436 M
Net income 2020 328 M
Finance 2020 2 498 M
Yield 2020 -
P/E ratio 2020 47,6x
P/E ratio 2021 23,7x
EV / Sales2020 5,44x
EV / Sales2021 4,40x
Capitalization 15 645 M
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 89,05  $
Last Close Price 72,17  $
Spread / Highest target 67,7%
Spread / Average Target 23,4%
Spread / Lowest Target -19,6%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul Alan Brooke Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-21.03%15 645
LONZA GROUP11.49%30 492
IQVIA HOLDINGS INC.-26.88%21 784
CELLTRION, INC.3.08%20 184
SEATTLE GENETICS, INC.0.90%19 860
GALAPAGOS-6.46%12 475